Articles Published in 2013

Evotec, Jain Foundation extend research collaboration

Thursday, August 29, 2013 11:00 AM

Evotec, a drug discovery alliance and development partnership company, and privately funded nonprofit the Jain Foundation have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.

More... »

Oxford BioMedica earns milestone payment from Pfizer

Thursday, August 29, 2013 10:01 AM

Oxford BioMedica, a gene-based biopharmaceutical company, has announced a $1 million milestone payment from Pfizer has been triggered by the entry of PF-06263507, a 5T4-targeted investigational antibody therapy, into human clinical trials.

More... »

Covidien opens Center of Innovation Korea

Thursday, August 29, 2013 09:00 AM

Covidien, a global provider of healthcare products, has opened the Covidien Center of Innovation Korea (CCI Korea), its first R&D and training and education center in Korea.

More... »

Northwestern Medicine enrolls first participant in brain tumor trial

Wednesday, August 28, 2013 02:47 PM

Northwestern Medicine recently joined a clinical trial to investigate if a vaccine made from a patient's own brain tumor is effective in slowing tumor progression and extending survival. The randomized, phase II trial will study how well giving the study vaccine with or without Avastin (bevacizumab) works in treating patients with recurrent glioblastoma multiforme (GBM).

More... »

Ambrx names Peter Kiener chief scientific officer

Wednesday, August 28, 2013 02:42 PM

Ambrx, a clinical stage biopharmaceutical company, has appointed Peter Kiener, Ph.D., chief scientific officer. Kiener has experience in the development of next-generation biologic therapeutics, including multi-specific, antibody based biologics, while president, chief executive officer and cofounder of Zyngenia.

Kiener led Zyngenia through its early stages of development, including validating the technology platform, identifying and advancing lead programs and securing Series A funding. Previously, Kiener was the executive vice president and global head of biologics R&D at MedImmune, AstraZeneca's biologics arm. He built protein and antibody engineering capabilities and oversaw the submission of multiple INDs and NDAs. Over the previous 18 years, Kiener held multiple positions at Bristol-Myers Squibb, 10 of which were spent working on biological therapeutics.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »

Akorn to acquire Hi-Tech Pharmacal

Wednesday, August 28, 2013 12:40 PM

Akorn, a niche pharmaceutical company developing, manufacturing and marketing multisource and branded pharmaceuticals with a focus on sterile ophthalmic and injectables, will acquire Hi-Tech Pharmacal, a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and over-the-counter (OTC) products,  for $640 million in cash.

More... »

Certara releases version 13 of Simcyp Simulator

Wednesday, August 28, 2013 12:37 PM

Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through development, has released version 13 of its Simcyp Simulator, which permits the quantitative prediction of drug-drug interactions and pharmacokinetic-pharmacodynamic outcomes in virtual populations.

More... »

Sangamo BioSciences to acquire Ceregene

Wednesday, August 28, 2013 12:35 PM

Sangamo BioSciences has agreed to acquire Ceregene, a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. 

More... »

PSI opens Italian office

Wednesday, August 28, 2013 12:34 PM

Global CRO PSI opened an operational office in Italy, expanding its presence in Europe and strengthening its ability to deliver global clinical trials. The office is located outside Milan.

More... »